Latest Eikon Therapeutics News & Updates

See the latest news and media coverage for Eikon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Eikon Therapeutics (Eikon)

Late-stage clinical biopharmaceutical company

eikontx.com
Headquarters
Millbrae, United States
Founded year
2019
Company type
Private company
Number of employees
400–500
Industry
Pharmaceuticals

Last updated

Latest news about Eikon Therapeutics (Eikon)

In short: Eikon Therapeutics reached key clinical and financial milestones, including a $381 million IPO and the start of a Phase 2/3 cancer trial.

Company announcements

Eikon

Eikon announces Phase 1/2 study of EIK1005 at ASCO 2026

The study evaluates EIK1005 as monotherapy and with pembrolizumab in advanced solid tumors, including MSI-H/dMMR.

Unlock all announcements with a

Media coverage

The Globe and Mail

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated...

Unlock all articles with a

Never miss news about Eikon

Track Eikon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Eikon competitors & trending companies

Browse news for competitors to Eikon and other trending companies.